Autophagy Markers in Endometrial Polyps

Investigation of Autophagy Markers in Endometrial Polyps

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04706000

Enrollment

Registered

2021-01-12

Start date

2021-01-08

Completion date

2022-02-01

Last updated

2023-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autophagy, Endometrial Polyp

Keywords

polyp, endometrium, beclin 1, LC3, p62

Brief summary

The aim of this research is to evaluate autophagy markers in patients with endometrial polyps

Detailed description

Endometrial polyp are benign formations that are frequently encountered in gynecology practice and have malignant potential. It may be asymptomatic in the clinic or may present with abnormal uterine bleeding. Although its pathophysiology has not been clearly revealed, there are many studies in the literature about it. However, the autophagy pathway emerges as a subject that has never been evaluated. In this study, the investigators would like to prospectively evaluate Beclin 1, LC3A / B and p62 markers in the autophagy pathway in endometrial polyp tissue samples by immunohistochemistry and reveal their importance.

Interventions

GENETICBeclin 1 gene

The determination of Beclin 1, LC3-II and p62 genes, which are evaluated by immunohistochemistry, at the protein level will be done by ELISA method in MSKU Medical Faculty Medical Biology Laboratory.

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

35 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Patients over 35 years of age with a histopathologically confirmed diagnosis of endometrial polyp * patients over the age of 35 whose histopathologically reported normal endometrial biopsy results.

Exclusion criteria

* Are under the age of 35, * those with cognitive dysfunction, * diagnosed with any type of cancer * who are under treatment for cancer, * diabetes mellitus, * hypertension, * endometriosis, * adenomyosis, * chronic endometritis, * have an acute or chronic illness, * patients who have smoked and used alcohol in the last 10 years

Design outcomes

Primary

Measure	Time frame	Description
autophagy marker	through study completion, an average of 1 year	Beclin 1 gene level

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026